Related references
Note: Only part of the references are listed.The Irish health-care system and austerity: sharing the pain
Steve Thomas et al.
LANCET (2014)
Purchasing factor concentrates in the 21st century through competitive tendering
C. R. M. Hay
HAEMOPHILIA (2013)
Haemophilia care in Europe - a survey of 35 countries
B. O'Mahony et al.
HAEMOPHILIA (2013)
Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)
C. L. Bacon et al.
HAEMOPHILIA (2011)
Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII
C. Rea et al.
HAEMOPHILIA (2009)
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose
M. Rubinger et al.
HAEMOPHILIA (2008)
Share Paper
